Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report) CEO Seth Lederman acquired 2,000 shares of the firm's stock in a transaction that occurred on Thursday, August 27th. The stock was purchased at an average price of $13.79 per share, with a total value of $27,580.00. Following the completion of the acquisition, the chief executive officer directly owned 11,005 shares of the company's stock, valued at $151,758.95. This represents a 22.21% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Seth Lederman also recently made the following trade(s):
- On Tuesday, June 9th, Seth Lederman acquired 5,000 shares of Tonix Pharmaceuticals stock. The stock was acquired at an average cost of $11.79 per share, with a total value of $58,950.00.
Tonix Pharmaceuticals Price Performance
Shares of Tonix Pharmaceuticals stock opened at $14.10 on Tuesday. The stock has a market cap of $241.81 million, a price-to-earnings ratio of -1.09 and a beta of 1.69. The firm's 50-day moving average is $12.02 and its two-hundred day moving average is $12.96. Tonix Pharmaceuticals Holding Corp. has a 1 year low of $9.40 and a 1 year high of $31.55.
Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last posted its quarterly earnings results on Monday, August 10th. The company reported ($2.44) EPS for the quarter, beating the consensus estimate of ($2.64) by $0.20. Tonix Pharmaceuticals had a negative net margin of 548.64% and a negative return on equity of 68.99%. The business had revenue of $13.54 million during the quarter, compared to analyst estimates of $7.72 million. On average, equities analysts expect that Tonix Pharmaceuticals Holding Corp. will post -10.03 earnings per share for the current year.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its position in Tonix Pharmaceuticals by 238.1% during the third quarter. Vanguard Group Inc. now owns 556,957 shares of the company's stock valued at $13,456,000 after acquiring an additional 392,225 shares during the last quarter. Balyasny Asset Management L.P. purchased a new position in Tonix Pharmaceuticals in the fourth quarter worth $2,895,000. Geode Capital Management LLC grew its holdings in Tonix Pharmaceuticals by 182.4% in the second quarter. Geode Capital Management LLC now owns 175,212 shares of the company's stock worth $6,305,000 after purchasing an additional 113,175 shares during the last quarter. Nuveen LLC increased its position in shares of Tonix Pharmaceuticals by 507.7% during the fourth quarter. Nuveen LLC now owns 93,402 shares of the company's stock worth $1,459,000 after purchasing an additional 78,033 shares in the last quarter. Finally, Capital Fund Management S.A. acquired a new position in shares of Tonix Pharmaceuticals during the third quarter worth $1,521,000. Institutional investors own 82.26% of the company's stock.
Analyst Upgrades and Downgrades
A number of research firms have weighed in on TNXP. Weiss Ratings lowered Tonix Pharmaceuticals from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday, July 28th. Wall Street Zen upgraded Tonix Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday. Raymond James Financial reissued a "strong-buy" rating and issued a $27.00 price target on shares of Tonix Pharmaceuticals in a research report on Monday, August 10th. Finally, TD Cowen upgraded Tonix Pharmaceuticals to a "strong-buy" rating in a research note on Tuesday, May 5th. Two analysts have rated the stock with a Strong Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $24.50.
Get Our Latest Analysis on TNXP
Tonix Pharmaceuticals Company Profile
(
Get Free Report)
Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company's pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.
Among Tonix's lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
